作为其更广泛投资组合优化战略的一部分，康梅德打算退出其消化病学产品线

Financial Considerations Related to the Exit

• Gastroenterology product lines are expected to generate $90 million to $95 million in revenue in 2025 with gross margins of approximately 45%.
• As a result of this strategic exit, the Company expects EPS dilution of $0.45–$0.55 in 2026.
• Exiting gastroenterology is projected to improve CONMED's consolidated gross margin profile by approximately 80 basis points after the exit is complete.
• CONMED plans to use the proceeds from the transaction with Gore for general corporate purposes including, but not limited to, strategic investments, debt paydown and share repurchases.
• CONMED does not expect a material impact on its 2025 financial results and is reaffirming its prior guidance range for revenue ($1.365–$1.372 billion) and adjusted EPS ($4.48–$4.53).